Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission1 compared with methotrexate (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission or improvement compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes clinical remission compared with 5‐ASA or Sulfasalzine (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in fistula improvement or healing compared with placebo (low certainty).
Azathioprine or 6‐mercaptopurine probably leads to higher steroid sparing effect compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
Azathioprine probably leads to lower clinical remission compared with infliximab (moderate certainty).
Azathioprine probably leads to lower clinical remission off steroids compared with infliximab (moderate certainty).
Azathioprine probably leads to lower mucosal healing compared with infliximab (moderate certainty).
The intervention showed no clear difference in induction of remission at 4 weeks (low certainty).
Budesonide 3 mg showed no clear difference in induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (low certainty).
Budesonide 15 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
Budesonide 15 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐… compared with placebo (low certainty).
Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 15 mg probably leads to lower withdrawal due to disease worsening compared with placebo (moderate certainty).